Aligos Therapeutics showcases advancements in chronic HBV and liver assets
Aligos Therapeutics (NASDAQ:ALGS) presented a series of clinical and preclinical data packages spanning its liver disease and viral portfolios, highlighting long-term tracking data from its lead drug candidate alongside several pipeline assets.
The South San Francisco-based biopharmaceutical firm introduced the data at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
The datasets focused heavily on therapeutic strategies targeting chronic hepatitis B virus (HBV), metabolic dysfunction-associated steatohepatitis (MASH), and hepatitis delta virus (HDV).
The company’s primary clinical presentation detailed post-treatment follow-up data from its Phase 1 study of pevifoscorvir sodium, an oral small-molecule capsid assembly modulator (CAM-E) under evaluation for chronic HBV.
The trial evaluated treatment-naïve or currently untreated HBeAg-positive subjects who underwent up to 96 weeks of pevifoscorvir sodium monotherapy, followed by a minimum of 24 weeks on standard nucleos(t)ide analog (NA) suppressive therapy.
According to the findings, patients transitioned to NA therapy maintained sustained control over baseline HBV DNA.
Notably, a portion of treated participants experienced substantial declines in hepatitis B surface antigen (HBsAg) levels.
Aligos noted that depressing HBsAg below critical thresholds via the drug's secondary mechanism of action may reduce the viral cccDNA reservoir, potentially enabling patients to qualify for subsequent, combination functional cure regimens, such as antisense oligonucleotides (ASOs).
Beyond its lead asset, Aligos utilized the international medical congress to display preclinical and early-stage profiles for its broader drug pipeline through multiple technical posters.
The company also highlighted its investigational antisense oligonucleotide ALG-170675, alongside targeted strategies for HDV.
Additionally, the drugmaker shared parameters for its small-molecule thyroid hormone receptor beta (THR-β) agonist, ALG-055009, and its targeted PD-1/PD-L1 inhibitor, ALG-093940, designed to address underlying immune exhaustion in chronic liver infections.
Management indicated that the cumulative findings support its strategic intent to position its core portfolio as baseline components of future combination therapies.
